[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637440":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":35,"locations":41,"responsibleParty":100,"collaborators":27,"id":102,"slug":103,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":27,"eligibilityCriteria":108,"healthyVolunteers":104,"sex":109,"minAge":110,"maxAge":27,"enrollmentInfo":111,"targetDuration":27,"studyType":114,"phases":115,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":87,"whyStopped":27,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},{"fullName":5,"class":6},"MiNK Therapeutics","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"agenT-797 plus SOC","EXPERIMENTAL","Participants will receive agenT-797 and SOC.",[13,14],"Drug: agenT-797","Drug: Standard of Care (SOC)",{"label":16,"type":17,"description":18,"interventionNames":19},"Placebo plus SOC","PLACEBO_COMPARATOR","Participants will receive placebo and SOC.",[20,14],"Drug: Placebo",[22,28,31],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","agenT-797","Intravenous infusion",[9],null,{"type":23,"name":29,"description":25,"armGroupLabels":30,"otherNames":27},"Placebo",[16],{"type":23,"name":32,"description":33,"armGroupLabels":34,"otherNames":27},"Standard of Care (SOC)","Antimicrobial therapy and corticosteroids per applicable guidelines.",[16,9],[36],{"name":37,"role":38,"phone":39,"phoneExt":27,"email":40},"MiNK Therapeutics Clinical Trial Information","CONTACT","1-212-994-8250","webmaster@minktherapeutics.com",[42,60,73,85],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"UCSF Medical Center at Parnassus Heights","NOT_YET_RECRUITING","San Francisco","California","94143","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-122.41942,37.77493,{"lat":54,"lon":53},[57],{"name":58,"role":59,"phone":27,"phoneExt":27,"email":27},"Michael Matthay, MD","PRINCIPAL_INVESTIGATOR",{"facility":61,"status":44,"city":62,"state":63,"zip":64,"country":48,"countryCode":49,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Children's Memorial Hermann Hospital","Houston","Texas","77030",{"type":51,"coordinates":66},[67,68],-95.36327,29.76328,{"lat":68,"lon":67},[71],{"name":72,"role":59,"phone":27,"phoneExt":27,"email":27},"Charles Cox, MD",{"facility":74,"status":44,"city":75,"state":63,"zip":76,"country":48,"countryCode":49,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"University Hospital","San Antonio","78229",{"type":51,"coordinates":78},[79,80],-98.49363,29.42412,{"lat":80,"lon":79},[83],{"name":84,"role":59,"phone":27,"phoneExt":27,"email":27},"Donald Jenkins, MD",{"facility":86,"status":87,"city":88,"state":27,"zip":89,"country":90,"countryCode":91,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"First Lviv Territorial Medical Union","RECRUITING","Lviv","79059","Ukraine","UA",{"type":51,"coordinates":93},[94,95],24.02324,49.83826,{"lat":95,"lon":94},[98],{"name":99,"role":59,"phone":27,"phoneExt":27,"email":27},"Chirstina Orlysnka, MD",{"type":101,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100637440","phase-2-a-clinical-trial-to-evaluate-agent-797-plus-standard-of-care-in-participants-with-severe-pneumonia-with-moderate-to-severe-acute-hypoxemic-respiratory-failure-100637440",false,"NCT07615010","A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure","Phase 2 Adaptive Randomized, Placebo -Controlled Trial of agenT-797 + Standard of Care Vs. Placebo + Standard of Care in Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure (AHRF) By Global ARDS Criteria","Key Inclusion Criteria:\n\n* Admission to an intensive care unit (ICU) with severe pneumonia of any etiology (viral, bacterial, fungal, or mixed), with and without trauma based on clinical suspicion\n* Acute hypoxemic respiratory failure (AHRF)\n* Evidence of moderate to severe acute respiratory distress syndrome (ARDS) based on Global ARDS criteria\n* Onset of severe pneumonia with AHRF ≤7 days prior to informed consent\n\nKey Exclusion Criteria:\n\n* More than two vasopressors to maintain a mean arterial pressure ≥65 millimeters of mercury at the time of informed consent\n* Pregnancy or breastfeeding\n* History of cytokine release syndrome, as documented in the medical record or reported by the participant, legally authorized representative, or close relative\n* Current participation in another interventional clinical trial, or receipt of an investigational medicinal product within 30 days prior to screening, unless reviewed and approved in writing by the medical monitor\n\nNote: Other protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","18 Years",{"count":112,"type":113},90,"ESTIMATED","INTERVENTIONAL",[116],"PHASE2","This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).",[119],"Pneumonia",[121,122,24],"Acute Hypoxemic Respiratory Failure","AHRF","2026-06-25",{"date":125,"type":126},"2026-06-26","ACTUAL",{"date":128,"type":126},"2026-05-26",{"date":130,"type":113},"2027-08",{"name":5,"class":6},4]